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I. Abstract 
Acute pancreatitis is a devastating inflammatory disease, which is initiated by the activation and 
retention of digestive zymogens inside pancreatic acinar cells. It is proposed that adenosine 
monophosphate-activated protein kinase (AMPK) regulates the early responses of acute 
pancreatitis in pancreatic acinar cells (acini). A recent in vitro study shows that induction of 
experimental pancreatitis in isolated rat pancreatic acini with supraphysiologic cerulein (an 
orthologue of the hormone cholecystokinin) causes an increase in intracellular zymogen 
activation, but a decrease in AMPK levels. Furthermore, in vitro pharmacologic stimulation of 
AMPK reduces zymogen activation, having a protective effect. In this study, the effectiveness of 
two AMPK activators was examined in two separate, clinically-relevant in vivo pancreatitis 
models. In the first model, Sprague-Dawley rats received a pre-treatment of the AMPK activator 
metformin via intraperitoneal (IP) injection. A second IP injection of cerulein was administered 
one hour later. One hour following the second injection, the rat pancreata were harvested and 
markers of pancreatitis were measured. Intracellular zymogen activation was assessed via trypsin 
activity, edema was assessed via percentage wet weight, and extent of cellular damage was 
assessed via histological staining. In the second model, C57/Bl6 mice received a pre-treatment of 
either metformin or salicylate (also an AMPK activator). For each of the six hours following, 
mice received an IP injection of cerulein. At the seventh hour, the pancreata were harvested. The 
same parameters were assessed. In both models, the AMPK activators displayed a marked 
decrease in intracellular zymogen activation. Edema data obtained through percentage wet 
weight measurements were found to be insignificant. Histological staining of pre-treated sections 
demonstrated a considerable decrease in edema and pyknotic nuclei in rats. These results 
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strongly suggest that metformin and salicylate could potentially be used as prophylactic or 
therapeutic treatments for patients early in the course of acute pancreatitis. 
II. Introduction 
Acute pancreatitis is described as a sudden inflammation of the pancreas. Pain and 
swelling in a patient’s upper left side of the abdomen is often a strong indicator of the disease. 
Other symptoms include nausea, vomiting, dehydration, and pain after food consumption. 
Clinical signs used to make a diagnosis include a swollen abdomen, fever, rapid pulse, and high 
amylase and lipase levels. Prognosis for acute pancreatitis ranges from mild to life-threatening, 
depending on cause as well as risk factors. Approximately 210, 000 patients are hospitalized with 
acute pancreatitis in the United States each year.[1] Treatment of this disease depends on both the 
cause and the severity. 
A pivotal step in the initiation of acute pancreatitis is the regulated conversion of 
digestive zymogens, such as trypsinogen and chymotrypsinogen, to their active forms, trypsin 
and chymotrypsin, and their retention within the pancreatic acinar cell. Subsequent studies have 
demonstrated that additional pathologic acinar cell responses, including reduced apical secretion, 
elaboration of inflammatory mediators, and development of a paracellular leak, are also observed 
in the early phases of the disease.[2] Later responses include reduced perfusion, inflammation, 
and cell death. 
The pancreatic acinar cell has the highest average rate of protein synthesis in the body.[3] 
This activity consumes high levels of ATP. Changes in acinar cell ATP levels have been reported 
in experimental acute pancreatitis models and the extent of ATP depletion in acute pancreatitis 
may correspond to disease severity. An important mechanism for energy sensing and 
conservation is AMP-activated protein kinase (AMPK).[3] AMPK is known to conserve cellular 
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energy by phosphorylating substrates to increase energy production or decrease activity of 
processes with high-energy consumption. One study has reported that acinar cell ATP levels 
change with pancreatitis stimuli, appearing to transiently increase, then fall.[4] Such fluctuations 
in ATP can potentially modulate AMPK activity during acute pancreatitis. 
AMPK is a heterotrimeric protein consisting of α, β, and γ subunits. The β and γ subunits 
both function as regulatory domains. The α subunit, however, is the catalytic domain and serves 
as the site of phosphorylation for AMPK. Specifically, phosphorylation occurs at the Thr172 
residue of the α subunit. 
A recent study performed by Shugrue et al. demonstrates the potential protective effect 
AMPK has in the pancreatic acinar cell.[5] This study explored the pharmacological modulation 
of AMPK and its effects on intracellular zymogen activation in cell culture. First, a group of 
isolated rat pancreatic acinar cells was treated with a hyperstimulatory concentration of cerulein 
(an orthologue of the hormone cholecystokinin), a substance commonly used to experimentally 
induce pancreatitis. A second group of acinar cells was first pre-treated with agents that enhance 
AMPK activity, namely AICAR and metformin. Then, the same hyperstimulatory dose of 
cerulein was introduced to these pre-treated acinar cells to induce pancreatitis. By using trypsin 
activity as a measure of intracellular zymogen activation, it was discovered that cells pre-treated 
with AMPK activating drugs displayed a striking reduction of cerulein-induced zymogen 
activation. This result was further supported through the pre-treatment of acinar cells with 
Compound C, an AMPK inhibitor. As anticipated, Compound C produced the opposite effect of 
AICAR and metformin; it increased cerulein-induced zymogen activation.[5] 
Given that this rat in vitro model exhibited a decrease in zymogen activation, a rat in vivo 
model was used to determine whether the effects of the AMPK activators would translate to 
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decreased severity of acute pancreatitis. Although the rat model is a well-characterized model 
that is useful for pancreatitis studies, the use of genetic knockout mice has been steadily 
increasing over recent years. For this reason, a mouse model was also developed as a part of this 
study. Attaining comparable results in mice could lay the foundation for transgenic studies. 
The two AMPK activators used in this study are metformin and salicylate. Although 
metformin and salicylate both activate AMPK, they do so using two completely different 
mechanisms of action. Metformin works indirectly on AMPK by mildly reducing the activity of 
the mitochondrial respiratory chain complex I.[6] The resulting decrease in ATP production puts 
the cell into a hepatic energy state. In this state, the amount of AMP and ADP in the cell are 
increased. The elevated AMP-to-ATP ratio causes the activation of AMPK. Salicylate, on the 
other hand, has a direct effect on AMPK. After AMPK is phosphorylated at Thr172, salicylate 
binds to the β subunit and acts as an allosteric activator.[7] The binding of salicylate also inhibits 
certain phosphatases from dephosphorylating AMPK. 
The results of this study provide evidence that pharmacological activation of AMPK in 




All experiments and procedures using animals were approved by the Veterans Affairs Healthcare 
System’s Institutional Animal Care and Use Committee (IACUC) in West Haven, CT. 
1a. In Vivo Rat Model. A 2-hour in vivo time-course was developed (Figure 1) whereby each 
Sprague-Dawley rat was given one initial IP injection and an additional IP injection one hour 
later. In the initial injection, each rat received either phosphate buffered saline (PBS control) or a 
 	   7	  
pre-treatment of metformin (MET) (120mg/kg). In the second injection, each rat received either 
PBS (control) or cerulein (40µg/kg). An hour following the second injection, the animals were 
euthanized; their pancreata were harvested and used to assess the following parameters of 
pancreatitis: intracellular zymogen activation, edema, and histological damage. This time-course 
resulted in four separate treatment groups requiring a total of 16 rats (4 per treatment group):     
1. PBS/PBS, 2. PBS/CER, 3. MET/PBS, 4. MET/CER. For simplicity, PBS/PBS will be 
referred to as PBS, MET/PBS as MET, and PBS/CER as CER. MET/CER will still be referred 
to as such. 
 
 
1b. Zymogen Activation Assay. Following harvest of pancreatic tissue, samples were 
homogenized in homogenization buffer [1.5 M Tris (pH 6.4), 0.3 M sucrose] and centrifuged at 
600g (4°C) for 10 minutes. The post-nuclear supernatant (PNS) (containing zymogen granules) 
of each sample was stored for assaying. For each sample, 10 µL of the PNS and 440 µL of 
zymogen assay buffer [50 mM Tris (pH 8.1), 150 mM NaCl, 1 mM CaCl2, 0.01% BSA] were 
both added to a well of a 24-well plate (Greiner Bio-one Cellstar TC-Plate). The assay was 
initiated by the addition of 50 µL of 400 mM trypsin substrate (fluorometric trypsin substrate; 
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Peptides International, Louisville, KY) diluted in zymogen assay buffer (40 mM final). The plate 
was read using a fluorometric microtiter plate reader (model HTS 7000; Perkin-Elmer Analytical 
Instruments, Shelton, CT.  380-nm excitation; 440-nm emission; 20 reads /10 min.). 
 
1c. Edema. Following the harvest of pancreatic tissue, each sample was blotted and its 
corresponding wet weight determined. The samples were then incubated at 60°C for 72 hours 
and reweighed. Edema was expressed as percent wet weight using the following equation: 
(Wet weight − Dry weight)/Wet weight  ×  100%. [8] 
 
1d. Histological Assessment. A 1-millimeter piece of pancreatic tissue was removed from each 
animal and was immersion fixed in 4% formalin. Then, the tissue was dehydrated, embedded in 
paraffin, sectioned (5 µm), and stained with hematoxylin and eosin. Slides were viewed using an 
Axiophot microscope (Carl Zeiss, Thornwood, NY) at 40x and 60x magnification and images 
were collected with a Spot Digital camera (Diagnostic Instruments, Sterling Heights, MI). 
Samples were assessed using a histological scoring system and representative images of each 
treatment group were selected. 
 
2a. In Vivo Mouse Model. A 7-hour in vivo time-course was developed (Figure 2) whereby each 
C57/Bl6 (Wild type or Wt) mouse was given a single IP injection every hour for 7 hours. In the 
initial injection, each mouse received either PBS control, a pre-treatment of MET (200mg/kg), or 
a pre-treatment of salicylate (SAL) (120mg/kg). For each of the six hours following, each mouse 
received either PBS (control) or CER (40µg/kg). At the seventh hour, the mice were euthanized; 
their pancreata were harvested and used to assess the following parameters of pancreatitis: 
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intracellular zymogen activation, edema, and histological damage. This time-course resulted in 
six separate treatment groups: 1. PBS/PBS, 2. MET/PBS, 3. SAL/PBS, 4. PBS/CER 5. 
MET/CER 6. SAL/CER. For simplicity, PBS/PBS will be referred to as PBS, MET/PBS as 
MET, SAL/PBS as SAL, and PBS/CER as CER. MET/CER and SAL/CER will still be referred 






2b. Zymogen Activation Assay. See Section 3.1b for procedure. 
2c. Edema. See Section 3.2c for procedure. 
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IV. Results 
1a. Zymogen activation (Rat). Metformin pre-treatment of the rats was found to significantly 
decrease cerulein-induced intracellular zymogen activation, as measured by trypsin activity 
(Figure 3). Although the MET rats presented a slight decrease in trypsin activity in comparison 
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1b. Edema (Rat). CER rats exhibited significant amounts of edema in comparison to PBS 
(control) rats (Figure 4). Specifically, CER rats had a percent wet weight of 80% whereas the 
PBS rats had approximately 65%. MET/CER rats experienced a 5% reduction in edema at 75% 
when compared to CER rats. The difference in edema between CER and MET/CER rats is 
statistically insignificant. Since this measure of edema is limited to the wet weight of the 
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1c. Histology (Rat). Histological assessment of sections gathered from pancreatic tissue from 
each of the four treatment groups is not consistent with the edema studies described above. It is 
evident that unlike the CER sections, the MET/CER sections show a substantial decrease in 
edema, pyknotic nuclei, and plasma membrane blebbing (Figure 5). PBS and MET are nearly 
identical and exhibit no cellular damage, as expected. The visual evidence of cellular damage 
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2a. Zymogen Activation (Mouse). Both metformin and salicylate pre-treatment of the rats were 
found to decrease cerulein-induced intracellular zymogen activation, as measured by trypsin 
activity (Figure 6). The two-fold decrease in trypsin activity between CER mice and SAL/CER 
mice was determined to be statistically significant. However, the decrease in trypsin activity 
between CER mice and MET/CER mice was found to only be approaching significance (p = 
0.0553). Increasing the number of animals in the MET/CER treatment group might have 
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2b. Edema (Mouse). CER rats exhibited significant amounts of edema in comparison to PBS 
(control) rats (Figure 7). Specifically, CER rats had a percent wet weight of 83% whereas the 
PBS rats had approximately 65%. MET/CER rats experienced an 8% reduction in edema at 75% 
when compared to CER rats. SAL/CER rats experienced a 10% reduction in edema at 83% when 
compared to CER rats. Neither MET/CER nor SAL/CER rats displayed a significant difference 
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2c. Histology (Mouse). Histological assessment of sections gathered from pancreatic tissue 
demonstrates clear histological damage in all sections of animals treated with CER (including 
MET/CER and SAL/CER) (Figure 8). This damage included severe edema, plasma membrane 
blebbing, and pyknotic nuclei. PBS, MET, and SAL showed no cellular damage. Damage in the 
pre-treated sections is thought to be the result of stress on the animals, as they received six 
injections in a matter of six hours. This amount of stress alone might have cause the damage in 
the pre-treated sections. 
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V. Discussion 
This study demonstrates that pre-treatment with the AMPK activators metformin and 
salicylate can lessen the severity of the early stages of acute pancreatitis in in vivo models. 
Although metformin and salicylate are able to lessen the pancreatitis responses by activating 
AMPK, cerulein causes an increase in pathological responses despite being able to activate 
AMPK. It has been shown that when cerulein activates AMPK, AMPK is translocated to an 
unidentified Triton X-100 insoluble compartment in the acinar cell, preventing AMPK from 
exerting its protective effects.[5] Now, a new set of questions arises: Do metformin and salicylate 
prevent this translocation and, if so, how? 
Three potential answers to this question are being considered. First, it is possible that 
metformin and salicylate are directly preventing the translocation of AMPK. By altering the 
conformation of one of the AMPK subunits, metformin and salicylate might prevent the 
translocation of AMPK. A chaperonin might also play a role in this potential mechanism. 
Second, cerulein might be stimulating additional pathways that move AMPK. Metformin and 
salicylate might be preventing these pathways from translocating active AMPK. Third, 
metformin and salicylate might be activating different AMPK proteins than cerulein, which 
could explain why AMPK activated by cerulein translocates away while AMPK activated by 
these drugs does not. 
An important point to note is the difference between prophylactic and therapeutic 
treatment. In this study, salicylate and metformin were considered to be prophylactic treatments, 
or pre-treatments. Prophylactic treatments such as this one could be useful in patients with 
hereditary pancreatitis.[9] Patients with hereditary pancreatitis often experience recurrent 
problems and undergoing prophylactic treatments of salicylate and metformin in low doses could 
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potentially be useful as a preventive measure. In addition, patients who undergo invasive 
procedures such as Endoscopic Retrograde Cholangeopancreatography (ERCP) could benefit 
from prophylactic treatment.[10] ERCP is used when a patient’s pancreatic or bile ducts are 
narrowed or fully blocked. The procedure makes use of an endoscope and X-rays for treatment. 
A major complication that frequently arises from this procedure is pancreatitis.[11] By 
administering prophylactic treatments to patients prior to undergoing ERCP, post-ERCP 
pancreatitis may be avoided. Future studies should also consider the therapeutic effect of 
salicylate, metformin, and additional AMPK activating drugs. 
It has also been discovered that different isoforms for each of the three AMPK subunits 
exist in the acinar cell. For instance, the α subunit can exist as α1 or α2, the β subunit can exist as 
β1 or β2, and the γ subunit can exist as γ1, γ2, or γ3 [12]. Theoretically, there are twelve possible 
isoform combinations for the protein AMPK (ex. α1β1γ1, α1β2γ2, etc.). Drugs that target a 
specific subunit of AMPK could be of greater therapeutic value if the abundance of each subunit 
is better determined. The use of AMPK-α1 and AMPK-α2 knockout mice should also be 
considered in future studies, as genetically reducing levels of AMPK in mice should confirm that 
salicylate and metformin are acting through AMPK. 
Since metformin and salicylate employ different mechanisms of action in activating 
AMPK, it may of great importance to consider the combination of MET and SAL as a potential 
prophylactic and therapeutic agent, as this combination may further reduce the severity of early 
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